A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-04-17
Target enrollment:
Participant gender:
Summary
The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating
doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard
chemotherapy consisting of gemcitabine and nab-paclitaxel. Blood and tumour samples for PK
and PD will be collected and assessments for determination of any clinical efficacy will be
completed.